Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$14.99
-0.6%
$15.94
$11.44
$18.92
$5.38B0.58437,515 shs292,188 shs
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$84.21
+2.5%
$69.33
$33.35
$86.00
$2.42B1.11459,937 shs478,819 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$130.20
+2.7%
$124.35
$73.16
$148.11
$7.45B0.831.30 million shs801,977 shs
Liquidia Corporation stock logo
LQDA
Liquidia
$71.80
+0.8%
$50.54
$11.85
$72.71
$6.33B0.571.75 million shs2.10 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%-2.56%-6.23%-8.49%+21.97%
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
0.00%+10.54%+24.91%+29.40%+119.39%
Glaukos Corporation stock logo
GKOS
Glaukos
0.00%+1.57%-11.68%+28.12%+29.76%
Liquidia Corporation stock logo
LQDA
Liquidia
0.00%+15.17%+25.12%+99.52%+405.18%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$14.99
-0.6%
$15.94
$11.44
$18.92
$5.38B0.58437,515 shs292,188 shs
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$84.21
+2.5%
$69.33
$33.35
$86.00
$2.42B1.11459,937 shs478,819 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$130.20
+2.7%
$124.35
$73.16
$148.11
$7.45B0.831.30 million shs801,977 shs
Liquidia Corporation stock logo
LQDA
Liquidia
$71.80
+0.8%
$50.54
$11.85
$72.71
$6.33B0.571.75 million shs2.10 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%-2.56%-6.23%-8.49%+21.97%
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
0.00%+10.54%+24.91%+29.40%+119.39%
Glaukos Corporation stock logo
GKOS
Glaukos
0.00%+1.57%-11.68%+28.12%+29.76%
Liquidia Corporation stock logo
LQDA
Liquidia
0.00%+15.17%+25.12%+99.52%+405.18%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.21
Hold$17.9219.49% Upside
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
2.67
Moderate Buy$87.143.48% Upside
Glaukos Corporation stock logo
GKOS
Glaukos
2.79
Moderate Buy$148.0013.67% Upside
Liquidia Corporation stock logo
LQDA
Liquidia
2.90
Moderate Buy$60.29-16.04% Downside

Current Analyst Ratings Breakdown

Latest ESTA, GKOS, LQDA, and BLCO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetBuy$140.00 ➝ $162.00
6/10/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Reiterated RatingBuy$162.00
6/8/2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Reiterated RatingBuy
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$67.00 ➝ $75.00
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Set Price Target$75.00
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Set Price Target$28.00
6/4/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Reiterated RatingStrong-Buy$68.00
6/2/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Set Price TargetBuy$19.00
5/26/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Reiterated RatingOutperform
5/21/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetBuy$141.00 ➝ $162.00
5/12/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$55.00 ➝ $67.00
(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$5.10B1.05$1.66 per share9.04$18.40 per share0.81
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$211.08M11.74N/AN/A$0.81 per share103.96
Glaukos Corporation stock logo
GKOS
Glaukos
$507.44M15.07N/AN/A$11.42 per share11.40
Liquidia Corporation stock logo
LQDA
Liquidia
$158.32M40.33N/AN/A$0.51 per share140.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$360M-$0.62N/A14.010.47-4.21%3.60%1.69%7/29/2026 (Estimated)
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$51.06M-$1.49N/A601.50N/A-19.05%-218.77%-12.31%8/6/2026 (Estimated)
Glaukos Corporation stock logo
GKOS
Glaukos
-$187.69M-$3.28N/A277.01N/A-34.34%-6.92%-5.25%7/29/2026 (Estimated)
Liquidia Corporation stock logo
LQDA
Liquidia
-$68.92M$0.14512.8914.93N/A7.74%46.82%7.06%8/11/2026 (Estimated)

Latest ESTA, GKOS, LQDA, and BLCO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Liquidia Corporation stock logo
LQDA
Liquidia
$0.4102$0.52+$0.1098$0.52$119.44 million$132.87 million
5/7/2026Q1 2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$0.3550-$0.45-$0.0951-$0.45$57.40 million$59.88 million
4/29/2026Q1 2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.08+$0.02-$0.20$1.22 billion$1.24 billion
4/29/2026Q1 2026
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.30-$0.18+$0.12-$0.34$137.00 million$150.57 million
3/18/2026Q4 2025
Liquidia Corporation stock logo
LQDA
Liquidia
$0.01$0.15+$0.14N/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
N/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Liquidia Corporation stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.78
1.53
0.99
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
16.82
2.96
1.91
Glaukos Corporation stock logo
GKOS
Glaukos
0.10
5.43
4.73
Liquidia Corporation stock logo
LQDA
Liquidia
1.18
2.22
2.03

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
72.91%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Liquidia Corporation stock logo
LQDA
Liquidia
64.54%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1.45%
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
9.99%
Glaukos Corporation stock logo
GKOS
Glaukos
5.90%
Liquidia Corporation stock logo
LQDA
Liquidia
25.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,000357.04 million351.87 millionOptionable
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
1,00429.43 million26.49 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
1,09458.73 million55.27 millionOptionable
Liquidia Corporation stock logo
LQDA
Liquidia
5088.93 million66.16 millionOptionable

Recent News About These Companies

Stephen Bloch Sells 242,269 Shares of Liquidia (NASDAQ:LQDA) Stock
Stephen Bloch Sells 145,954 Shares of Liquidia (NASDAQ:LQDA) Stock
Liquidia Corporation
Stephen Bloch Sells 148,301 Shares of Liquidia (NASDAQ:LQDA) Stock
Stephen Bloch Sells 72,534 Shares of Liquidia (NASDAQ:LQDA) Stock
Liquidia Added to S&P SmallCap 600 Index

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$14.99 -0.09 (-0.57%)
Closing price 03:59 PM Eastern
Extended Trading
$15.00 +0.01 (+0.04%)
As of 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Establishment Labs stock logo

Establishment Labs NASDAQ:ESTA

$84.21 +2.07 (+2.52%)
Closing price 04:00 PM Eastern
Extended Trading
$84.10 -0.11 (-0.14%)
As of 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

Glaukos stock logo

Glaukos NYSE:GKOS

$130.20 +3.39 (+2.67%)
Closing price 03:59 PM Eastern
Extended Trading
$133.99 +3.79 (+2.91%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Liquidia stock logo

Liquidia NASDAQ:LQDA

$71.80 +0.57 (+0.80%)
Closing price 04:00 PM Eastern
Extended Trading
$71.00 -0.80 (-1.12%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.